Option chain shows key data for UCB's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for UCB.

UCB (OTC:UCBJY) Stock, Option Chain

UCB ADR

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Biogen - logo

Biotech

Large Cap

News

Health Care

General

BIIB

UCBJF

UCBJY

UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48 weeks.

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

bz_pharma_briefs

Analyst Color

Initiation

Analyst Ratings

LBPH

Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets.

Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage

Johnson Johnson logo in front of one of their office buildings, Fremont, East San Francisco bay area, California. Image By Sundry Photography Via Shutterstock

ARGX

Johnson &amp; Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows positive Phase 3 study results and could position nipocalimab as a key competitor against existing gMG treatments like UCB&#39;s Rystiggo and Argenx&#39;s Vyvgart.

Johnson &amp; Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

UCB SA

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €175.00. The company...

Barclays Keeps Their Buy Rating on UCB SA (0NZT)

Leerink says UCB's (UCBJF) announcement that Roche (RHHBY) terminated collaboration on its Alzheimer's disease asset is bringing negative sentiment...

Voyager Therapeutics selloff on UCB news 'excessive,' says Leerink

UBS analyst Xian Deng maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €180.00. The company's shares clos...

UCB SA (0NZT) Gets a Buy from UBS

Artisan International Fund Q3 2024 Commentary

Barclays Sticks to Its Buy Rating for UCB SA (0NZT)

In a report released today, Xian Deng from UBS maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of €200.00. The comp...

UBS Remains a Buy on UCB SA (0NZT)

Jefferies analyst Brian Balchin maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €212.00. The company's s...

Jefferies Sticks to Its Buy Rating for UCB SA (0NZT)

Barclays Remains a Buy on UCB SA (0NZT)

Deutsche Bank raised the firm's price target on UCB (UCBJF) to EUR 215 from EUR 200 and keeps a Buy rating on the shares. Published first on TheFly...

UCB price target raised to EUR 215 from EUR 200 at Deutsche Bank

ACCYY

ACRFF

AIQUF

AIQUY

AMZN

ARGNF

ASML

ASMLF

AZNCF

EADSF

EADSY

ENGIY

ENGQF

HEINY

HINKF

JPPTY

JPSTF

MLSPF

NGGTF

NPXYY

OTSKF

OTSKY

PDRDF

PRNDY

RHHBY

RHHVF

RSNHF

SMFG

SMFNF

TMNSF

TMSNY

TYNPF

VYGR

Press Releases

New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels

FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia

Entertainment

UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price!

UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Comments

UCB

UCB (UCBJY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga